This $194,013 Project Grant award from the National Cancer Institute (NCI), under CFDA 93.395 Cancer Treatment Research, aims to develop a new monoclonal antibody therapy for the treatment of small cell lung cancer (SCLC). The key products and services to be delivered include:
-
Generation of a mouse monoclonal antibody specifically targeting the isoaspartylated form of the ELAVL4 protein, which is expressed on the surface of SCLC tumors and can elicit an immune response in some patients. The binding kinetics and affinity of candidate antibodies will be optimized.
-
Testing the therapeutic efficacy of the anti-isoaspartyl-ELAVL4 monoclonal antibody in a mouse model of SCLC, using survival as the primary endpoint. If successful, the antibody would be humanized for potential clinical trials in SCLC patients.
The award will be administered by the University of Southern California over a 2-year period from April 1, 2025 to March 31, 2027. The project leverages the university's expertise in cancer research and immunology to advance a novel targeted therapy approach for this highly aggressive form of lung cancer.
Generated 3/25/25, 5:52 AM